Data Visualization7 min readUpdated 2026-04-03

    How GLP-1 Medications Change Your Body: Visual Guide to Every System Affected

    Visual infographic showing how semaglutide, tirzepatide, and retatrutide affect every body system -- brain, heart, liver, gut, pancreas, and more.

    Key Insight

    GLP-1 medications do far more than suppress appetite. They affect virtually every major organ system, providing cardiovascular protection, liver healing, anti-inflammatory effects, and potential neuroprotection. Weight loss is just the most visible benefit.

    Body System Effects Map

    Semaglutide, tirzepatide, and retatrutide work through GLP-1 receptors found throughout the body. This visual guide shows how each system benefits from treatment.

    Brain

    • +Reduces appetite signals
    • +Decreases food noise and cravings
    • +May reduce addiction behaviors
    • +Potential neuroprotective effects

    Heart

    • +Reduces cardiovascular risk 20%
    • +Lowers blood pressure 5-10 mmHg
    • +Reduces inflammation markers
    • +Improves cholesterol profile

    Liver

    • +Reduces liver fat by 50-70%
    • +Improves MASH/NAFLD markers
    • +Normalizes liver enzymes
    • +Reduces fibrosis progression

    Stomach & Gut

    • +Slows gastric emptying
    • +Increases satiety signals
    • +May improve gut microbiome
    • +Reduces acid reflux in some patients

    Additional Body Effects

    Pancreas

    Enhances insulin secretion, protects beta cells, improves blood sugar control

    Kidneys

    Renal protective effects, reduces albuminuria, slows CKD progression

    Immune System

    Reduces CRP, decreases systemic inflammation, may improve autoimmune markers

    Joints

    Reduced load on joints, decreased inflammation, improved mobility

    Skin

    Improved circulation, reduced inflammation-related conditions, potential collagen effects

    Sleep

    Reduced sleep apnea severity, improved sleep quality, better oxygenation

    Medical Disclaimer: This content is for informational purposes only. Not all effects are experienced by every patient. Consult your healthcare provider for personalized guidance.

    Frequently Asked Questions

    What organs does GLP-1 medication affect?

    GLP-1 receptors are found throughout the body. Medications affect the brain (appetite reduction), stomach (slowed emptying), pancreas (insulin secretion), liver (reduced fat), heart (cardiovascular protection), kidneys (renal protection), and even the immune system (anti-inflammatory effects).

    Are the body changes from GLP-1 permanent?

    Some changes persist after stopping medication (improved metabolic health, reduced inflammation markers) while others reverse (appetite returns, weight may regain). Maintaining a healthy lifestyle preserves more benefits long-term.

    How quickly do body changes happen?

    Brain effects (appetite reduction) begin within days. Cardiovascular improvements measurable within weeks. Liver fat reduction within 3-6 months. Body composition changes visible by month 2-3. Full metabolic benefits develop over 6-12 months.

    Do different GLP-1 medications affect the body differently?

    Semaglutide primarily targets GLP-1 receptors. Tirzepatide adds GIP receptor activation for enhanced insulin sensitivity. Retatrutide adds glucagon receptor activation for increased fat burning and liver benefits. More receptors means more body systems engaged.

    Transform Your Whole Body

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: November 22, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Visual timeline showing what to expect each week and month on GLP-1 medications. Weight loss milestones, side effect patterns, and body changes mapped out.

    Visual step-by-step dosing guide showing titration schedules, dose escalation timelines, and what to expect at each dose level for all GLP-1 medications.

    Visual comparison of side effect rates across all GLP-1 medications. Data-driven chart showing nausea, vomiting, diarrhea, and other side effects by medication and dose.

    Visual map of every GLP-1 and weight loss medication currently in clinical trials, from Phase 1 through FDA approval. See what is coming next after semaglutide and tirzepatide.

    Start your GLP-1 journey — from $99/mo

    Get Started